Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...
Equity Markets Recover on Strength in Defensive Stocks and Energy Producers
Better-than-expected economic news from China also supported stocks after the China March manufacturing PMI rose +0.3 to 50.5, better than expectations of 50.4 and the strongest report in a year. In ...
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
Fintel on MSN23h
RBC Capital Downgrades Sarepta Therapeutics (SRPT)
Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
RBC downgrades Sarepta on ‘less bullish’ stance after doctor checks
RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...
Mizuho Securities Remains a Buy on Sarepta Therapeutics (SRPT)
Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...